Industry

City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors

City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumors. SYDNEY & LOS ANGELES–(BUSINESS WIRE)–Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed … [Read more…]

CORRECTING and REPLACING Linear Health Sciences Announces U.S. FDA Clearance and Health Canada Approval of Its Orchid Safety Release Valve (SRV)

Device Intended to Reduce Risk of IV Catheter Failure and Replacement in Hospitals; Sister Product Orchid SRV-Type D for Drainage to Launch Simultaneously OKLAHOMA CITY–(BUSINESS WIRE)–#FDA–Please replace the release with the following corrected version due to the removal of paragraph eight (“Linear Health Sciences won an Innovative Technology Award for Orchid SRV from Vizient, and … [Read more…]

CAP Statement on the Release of the Senate’s FDA User Fee Authorization Bill

WASHINGTON–(BUSINESS WIRE)–The College of American Pathologists (CAP) President Emily Volk, MD, FCAP, released the following statement regarding the draft Food and Drug Administration (FDA) user fee authorization bill by the Senate Health, Education, Labor, and Pensions (HELP) Committee. The discussion draft of the bill includes sections of the Verifying Accurate Leading-edge IVCT Development (VALID) Act … [Read more…]

CLEAResult Launches Carbon Consulting Practice to Guide Businesses Towards Sustainability

AUSTIN, Texas–(BUSINESS WIRE)–#carbonfootprint–Businesses are being held accountable for their environmental impact. Some companies have taken a proactive approach by announcing their plans to reach net zero, while others are considering more modest reductions to reduce operational expenditures. A few weeks ago, the Securities and Exchange Commission (SEC) issued a proposal requiring public companies to disclose … [Read more…]

Geron to Present at the H.C. Wainwright Global Investment Conference

FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference. The presentation will be available as an … [Read more…]

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that company management will present at the upcoming H.C. Wainwright Global Life Sciences Conference. A pre-recorded presentation will become available to registered conference attendees on May 24, … [Read more…]

Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting

– Late-Breaking TROPiCS-02 Study Results in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients to be Featured in ASCO Press Program – – New Sub-Analysis from Kite’s ZUMA-7 CAR T-cell Therapy Study in Patients Aged 65+ and Data by Tumor Burden Characteristics in Second-Line Large B-cell Lymphoma to be Presented – – Diverse Hematologic Research to … [Read more…]

The EQUITY Coalition Responds to Governor Newsom’s May Budget Revise

Proposed budget falls short of addressing urgent gaps in health data sharing despite $97.5 billion budget surplus SACRAMENTO, Calif.–(BUSINESS WIRE)–The data sharing EQUITY Coalition, made up of more than 25 health plans, provider groups, and health information organizations, released the following statement in response to Governor Newsom’s May Revision to the CA 2022-23 budget proposal: … [Read more…]

Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting

Emendo Biotherapeutics revealed pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an allele-specific editing approach, generating a highly specific editing composition that achieves both no off-targets and complete allele specificity, in oral presentation at ASGCT annual meeting by Emendo Executive VP R&D Rafi Emmanuel, Ph.D. Emendo also presented three posters at ASGCT, … [Read more…]

Phreesia’s Danielle Lynch Named a ‘Sales MVP’ in PM360’s ELITE 100

RALEIGH, N.C.–(BUSINESS WIRE)–Phreesia is pleased to announce that the healthcare marketing industry trade publication PM360 has named Danielle Lynch, Vice President, Client Experience, as one of the 2022 PM360 ELITE 100. The PM360 ELITE Awards recognize the most influential people in the healthcare and life sciences industry today, and honorees were chosen from a pool … [Read more…]